Search results
Jul 18, 2023 · Key points: A study showed donanemab could slow Alzheimer's disease progression by 35pc in patients in the earliest stages of the disease. Geriatrician Michael Woodward says the medical community is excited by the results. The donanemab study findings were similar to those of its predecessor lecanemab.
Associate Professor Michael Woodward is Head of Aged Care Research and the Memory Clinic at Austin Health in Melbourne, Victoria. He is a specialist in geriatric medicine with major interests in the treatment of Alzheimer’s disease (AD) and other dementias.
- So What's All The Controversy About?
- 'One of The Safer Drugs'
- Like A Light Turning Back on
- How Will Regulators Deal with Aducanumab?
- GeneratedCaptionsTabForHeroSec
Alzheimer's experts agree the drug helps reduce the build-up of amyloid plaques. What they disagree on is whether it takes the outward symptoms of Alzheimer's disease with it. It stems from a fierce scientific debate about whether a protein called beta-amyloid plaque (BAP) or another protein called tau are responsible for Alzheimer's, or a combinat...
Her colleague Associate Professor Michael Woodward, a geriatrician who has been involved in Alzheimer's research for decades, is more optimistic. "It reduces the rate of decline by about 30 per cent," he said. "So it doesn't improve cognition, but it slows down the decline considerably." He believed the ARIA threat could be managed like all other h...
Ask Sylvia Johnson and she'll tell you all these risks are worth it. The 74-year-old said during the first trial in 2019 it was "like someone turned a light back on". "It was gradual, but you could see that it was working, I could read a book again," she said. She was devastated when those trials were halted abruptly. "I just burst into tears. I wa...
Following the early controversies, in the US the FDA has since narrowed the scope of aducanumab's use to the early stages of the disease. The FDA has also asked the US auditor-general to investigate reports of an undocumented meeting between the drug's makers Biogen and regulators during the approval process. In a statement, Biogen said it stood by...
Aducanumab is a controversial drug that removes amyloid plaque from the brain, but may cause brain bleeds. Associate Professor Michael Woodward, a geriatrician, supports its use, while Professor Amy Brodtmann, a cognitive neurologist, questions its effectiveness.
Associate Professor Michael Woodward is Head of Aged Care Research and the Memory Clinic at Austin Health in Melbourne, Victoria. He is a specialist in geriatric medicine with major interests in the treatment of Alzheimer’s disease (AD) and other dementias.
Jun 18, 2012 · Associate Professor Michael Woodward is head of aged and residential care services at Austin Health, and a geriatrician in private practice at Donvale Rehabilitation Hospital. He is director of the Austin’s wound management clinic, editor of Wound Practice and Research and a past president of the Australian Wound Management ...
- Sophie McNamara
- 2012
Michael Woodward may refer to: Michael Woodward, British priest tortured aboard the Chilean naval vessel Esmeralda; Michael Woodward (academic) (1602–1675), English educational administrator
A/Prof Michael Woodward AM is a geriatrician and a leader in vaccine research and promotion for older people. He has written and spoken on topics such as shingles, RSV, Souvenaid, and immunisation gaps in older Australians.
